Search

The Phage Australia Clinical Network has published the STAMP Protocol for phage therapy. This is an open-label, single-arm trial investigating a standardised treatment and monitoring protocol for phage therapy. The aim is to recruit 50–100

The National Institute of Allergy and Infectious Diseases (NIAID) has begun a clinical trial for phage therapy in adults with cystic fibrosis, under the leadership of IPATH. The trial plans to enroll 72 participants across 16 cystic fibrosi

News: Locus Biosciences announces first patient treated in the ELIMINATE phase 2/3 trial for urinary tract infections.

BiomX has reported findings from a phase 1a clinical trial of its K. pneumoniae-specific phage candidate BX002. They randomized 18 healthy adults to take either a phage cocktail or placebo orally. They looked at viable phage in stool, and c

Adaptive Phage Therapeutics announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision phage therapy in patient

Armata Pharmaceuticals announces first patient dosed in phase 1b/2a 'diSArm' study of AP-SA02 in adults with bacteremia due to Staphylococcus aureus.

Intralytix has been granted FDA clearance for an investigational new drug application for phase 1/2a clinical trials for vancomycin resistant Enterococci (VRE)-targeting phage.

Clinical trial: Armata Pharmaceuticals announces clearance of investigational new drug application to initiate phase 2 clinical trial of AP-PA02 in non-cystic fibrosis bronchiectasis.

Clinical trial approval: Pherecydes Pharma obtains ANSM Approval for its PhagoDAIR program, which treats osteoarticular infections of prosthetic joints caused by Staphylococcus aureus.

In an effort to help companies navigate the development of their bacteriophage product, IHMA’s VP Global Microbiology Services & CSO, Daniel Sahm has compiled a summary of key considerations to address prior to beginning clinical trials.

In an effort to help companies navigate the development of their bacteriophage product, IHMA’s VP Global Microbiology Services & CSO, Daniel Sahm has compiled a summary of key considerations to address prior to beginning clinical trials.

TechnoPhage announces first clinical safety results with their phage cocktail, TP-102, now advancing to phase 2. TP-102 is assessed for its safety and tolerability in individuals with diabetic foot ulcers, and showed no adverse effects in t

Adaptive Phage Therapeutics announced a strategic agreement with the Antibacterial Resistance Leadership Group to support a phase 1b/2 cystic fibrosis (CF) study. The randomized, double-blind, placebo-controlled trial will assess the safety

Austen Terwilliger (TAILOR Labs, Baylor College of Medicine, Texas) and colleagues have published a new paper in Viruses on phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract

Adaptive Phage Therapeutics dosed the first patient in their phase 1/2 study to evaluate their PhageBank™ technology as a treatment for UTIs.

Felix Biotechnology, alongside researchers at Yale University (including labs of Paul Turner, Ben Chan and Jon Koff), are recruiting patients for a cystic fibrosis phage therapy clinical trial! If interested, please contact claire.cochrane@

Adaptive Phage Therapeutics (APT) announced that the FDA has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). This is the third successful IND appli

Locus Biosciences announced the completion of a phase 1b trial of CRISPR-Cas3-enhanced phage targeting E. coli in urinary tract infections. The trial met all the endpoints, and represents the first randomized, placebo-controlled trial using

TechnoPhage has initiated a phase I/IIa study to test a phage treatment for diabetic foot infections. This product is the first of TechnoPhage’s pipeline to enter clinical trials, constituting an exciting milestone for the company. The resu

FDA has cleared Adaptive Phage Therapeutics to start formally investigating use of its PhageBank™ to treat prosthetic joint infections. This gives APT the green light to start a phase 1/2 clinical trial in the first half of 2021 in collabor